We should prohibit warfarin in idiopathic pulmonary fibrosis

American Journal of Respiratory and Critical Care Medicine

Volumn 191, Issue 8, 2015, Pages 958-960

  Alagha, Khuder ^a   Secq, Veronique ^b   Pahus, Laurie ^a   Sofalvi, Tunde ^a   Palot, Alain ^a   Bourdin, Arnaud ^c   Chanez, Pascal ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c MONTPELLIER UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DABIGATRAN; HEPARIN; PREDNISOLONE; PREDNISONE; WARFARIN; ANTICOAGULANT AGENT;

ADULT; AGED; CASE REPORT; COUGHING; DISEASE EXACERBATION; DRUG CONTRAINDICATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FIBROSING ALVEOLITIS; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; LEG PAIN; LETTER; MALE; MIDDLE AGED; OXYGEN THERAPY; PRIORITY JOURNAL; THROMBOPHLEBITIS; ATRIAL FIBRILLATION; COMPLICATION; FATALITY;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; FATAL OUTCOME; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; MIDDLE AGED; THROMBOPHLEBITIS; WARFARIN;

EID: 84927785938     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201412-2281LE     Document Type: Letter

References (15)

1. Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE Jr, Lasky JA, Loyd JE, Noth I, Olman MA, et al.; Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007;176:636-643.
2. Noth I, Anstrom KJ, Calvert SB, de Andrade J, Flaherty KR, Glazer C, Kaner RJ, Olman MA; Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet). A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012;186:88-95.
3. Cottin V, Crestani B, Valeyre D, Wallaert B, Cadranel J, Dalphin JC, Delaval P, Israel-Biet D, Kessler R, Reynaud-Gaubert M, et al.; French National Reference and Competence Centers for Rare Diseases; Société de Pneumologie de Langue Française. French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis. From the National Reference and the Competence centers for rare diseases and the Société de Pneumologie de Langue Française [in French]. Rev Mal Respir 2013;30:879-902.
4. Kotani I, Sato A, Hayakawa H, Urano T, Takada Y, Takada A. Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis. Thromb Res 1995;77:493-504.
5. Hernández-Rodríguez NA, Cambrey AD, Harrison NK, Chambers RC, Gray AJ, Southcott AM, du Bois RM, Black CM, Scully MF, McAnulty RJ, et al. Role of thrombin in pulmonary fibrosis. Lancet 1995;346:1071-1073.
6. Tani K, Yasuoka S, Ogushi F, Asada K, Fujisawa K, Ozaki T, Sano N, Ogura T. Thrombin enhances lung fibroblast proliferation in bleomycininduced pulmonary fibrosis. Am J Respir Cell Mol Biol 1991;5:34-40.
7. Bogatkevich GS, Gustilo E, Oates JC, Feghali-Bostwick C, Harley RA, Silver RM, Ludwicka-Bradley A. Distinct PKC isoforms mediate cell survival and DNA synthesis in thrombin-induced myofibroblasts. Am J Physiol Lung Cell Mol Physiol 2005;288:L190-L201.
8. Bogatkevich GS, Tourkina E, Silver RM, Ludwicka-Bradley A. Thrombin differentiates normal lung fibroblasts to a myofibroblast phenotype via the proteolytically activated receptor-1 and a protein kinase C-dependent pathway. J Biol Chem 2001;276:45184-45192.
9. Piguet PF, Van GY, Guo J. Heparin attenuates bleomycin but not silica-induced pulmonary fibrosis in mice: possible relationship with involvement of myofibroblasts in bleomycin, and fibroblasts in silicainduced fibrosis. Int J Exp Pathol 1996;77:155-161.
10. Howell DC, Goldsack NR, Marshall RP, McAnulty RJ, Starke R, Purdy G, Laurent GJ, Chambers RC. Direct thrombin inhibition reduces lung collagen, accumulation, and connective tissue growth factor mRNA levels in bleomycin-induced pulmonary fibrosis. Am J Pathol 2001;159:1383-1395.
11. Kubo H, Nakayama K, Yanai M, Suzuki T, Yamaya M, Watanabe M, Sasaki H. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 2005;128:1475-1482.
12. Yasui H, Gabazza EC, Taguchi O, Risteli J, Risteli L, Wada H, Yuda H, Kobayashi T, Kobayashi H, Suzuki K, et al. Decreased protein C activation is associated with abnormal collagen turnover in the intraalveolar space of patients with interstitial lung disease. Clin Appl Thromb Hemost 2000;6:202-205.
13. Yasui H, Gabazza EC, Tamaki S, Kobayashi T, Hataji O, Yuda H, Shimizu S, Suzuki K, Adachi Y, Taguchi O. Intratracheal administration of activated protein C inhibits bleomycin-induced lung fibrosis in the mouse. Am J Respir Crit Care Med 2001;163:1660-1668.
14. Bogatkevich GS, Ludwicka-Bradley A, Silver RM. Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts. Arthritis Rheum 2009;60:3455-3464.
15. Bogatkevich GS, Ludwicka-Bradley A, Nietert PJ, Akter T, van Ryn J, Silver RM. Antiinflammatory and antifibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease. Arthritis Rheum 2011;63:1416-1425.